October 26, 2018

Orgenesis, Hemogenyx Collaborating on Cell Replacement Technology for Blood Cancers

News

Orgenesis has partnered with Hemogenyx Pharmaceuticals to drive the development and commercialization of Hemogenyx’s human postnatal hemogenic endothelial cell (Hu-PHEC) technology for the treatment of blood cancers. Hu-PHEC is a cell replacement technology designed ... Read more

August 16, 2018

Cellectar and Orano Med Collaborating to Advance Innovative Anti-Cancer Therapy

News

Cellectar Biosciences and Orano Med, two companies using distinct strategies to develop innovative therapies for cancer, are joining forces to advance a class of anti-cancer therapies called phospholipid drug conjugates. ... Read more